Patents by Inventor Thomas H. Marsilje, III

Thomas H. Marsilje, III has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Compounds and compositions for modulating EGFR Activity
    Patent number: 9440957
    Abstract: The invention provides compounds and pharmaceutical compositions thereof, which are useful for modulating EGFR activity, as well as methods for using such compounds to treat, ameliorate or prevent a condition associated with abnormal or deregulated EGFR activity.
    Type: Grant
    Filed: June 5, 2013
    Date of Patent: September 13, 2016
    Assignee: Novartis AG
    Inventors: Gerald Lelais, Robert Epple, Thomas H. Marsilje, III, Pierre-Yves Michellys, Matthew McNeill, Yun Long, Wenshuo Lu, Bei Chen, Badry Bursulaya, Songchun Jiang
  • Compounds and Compositions for Modulating EGFR Activity
    Publication number: 20150197505
    Abstract: The invention provides compounds and pharmaceutical compositions thereof, which are useful for modulating EGFR activity, as well as methods for using such compounds to treat, ameliorate or prevent a condition associated with abnormal or deregulated EGFR activity.
    Type: Application
    Filed: June 5, 2013
    Publication date: July 16, 2015
    Applicant: IRM LLC, A Delaware Limited Liability Company
    Inventors: Gerald Lelais, Robert Epple, Thomas H. Marsilje, III, Pierre-Yves Michellys, Matthew McNeill, Yun Long, Wenshuo Lu, Bei Chen, Badry Bursulaya Bursulaya, Songchun Jiang
  • Compounds and Compositions for Modulating EGFR Activity
    Publication number: 20150152083
    Abstract: The invention provides compounds and pharmaceutical compositions thereof, which are useful for modulating EGFR activity, as well as methods for using such compounds to treat, ameliorate or prevent a condition associated with abnormal or deregulated EGFR activity.
    Type: Application
    Filed: June 5, 2013
    Publication date: June 4, 2015
    Applicant: IRM LLC, A Delaware Limited Liability Company
    Inventors: Gerald Lelais, Robert Epple, Pierre-Yves Michellys, Badry Bursulaya, Songchun Jiang, Thomas H. Marsilje III, Matthew MCneill
  • COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS
    Publication number: 20150105390
    Abstract: The invention provides novel pyrimidine and pyridine derivatives and pharmaceutical compositions thereof, and methods for using such compounds. For example, the pyrimidine and pyridine derivatives of the invention may be used to treat, ameliorate or prevent a condition which responds to inhibition of anaplastic lymphoma kinase (ALK) activity, focal adhesion kinase (FAK), zeta-chain-associated protein kinase 70 (ZAP-70), insulin-like growth factor (IGF-1R), or a combination thereof.
    Type: Application
    Filed: December 17, 2014
    Publication date: April 16, 2015
    Applicant: IRM LLC, a Delaware Limited Liability Company
    Inventors: Pierre-Yves Michellys, Wei Pei, Thomas H. Marsilje, III, Wenshuo Lu, Bei Chen, Tetsuo Uno, Yunho Jin, Tao Jiang
  • Compounds and compositions as protein kinase inhibitors
    Patent number: 8957081
    Abstract: The invention provides novel pyrimidine and pyridine derivatives and pharmaceutical compositions thereof, and methods for using such compounds. For example, the pyrimidine and pyridine derivatives of the invention may be used to treat, ameliorate or prevent a condition which responds to inhibition of anaplastic lymphoma kinase (ALK) activity, focal adhesion kinase (FAK), zeta-chain-associated protein kinase 70 (ZAP-70), insulin-like growth factor (IGF-1R), or a combination thereof.
    Type: Grant
    Filed: September 11, 2012
    Date of Patent: February 17, 2015
    Assignee: IRM LLC
    Inventors: Pierre-Yves Michellys, Wei Pei, Thomas H. Marsilje, III, Bei Chen, Tetsuo Uno, Yunho Jin, Tao Jiang
  • FLUOROPHENYL BICYCLIC HETEROARYL COMPOUNDS
    Publication number: 20130338152
    Abstract: The present invention provides a compound the invention, and its use as a IGF-1R inhibitor. The present invention further provides a combination of pharmacologically active agents and a pharmaceutical composition.
    Type: Application
    Filed: March 8, 2012
    Publication date: December 19, 2013
    Applicants: IRM LLC, NOVARTIS AG
    Inventors: Bei Chen, Robin Alec Fairhurst, Songchun Jiang, Wenshuo Lu, Thomas H. Marsilje, III, Clive McCarthy, Pierre-Yves Michellys, Stefan Stutz
  • Pyrimidine derivatives as kinase inhibitors
    Patent number: 8519129
    Abstract: The invention provides novel pyrimidine derivatives of formula I and pharmaceutical compositions thereof, and methods for using such compounds. For example, the pyrimidine derivatives of the invention may be used to treat, ameliorate or prevent a condition which responds to inhibition of insulin-like growth factor (IGF-IR) or analplastic lymphoma kinase (ALK).
    Type: Grant
    Filed: June 24, 2009
    Date of Patent: August 27, 2013
    Assignee: IRM LLC
    Inventors: Thomas H. Marsilje, III, Wenshuo Lu, Bei Chen, Xiaohui He, Christian Cho-Hua Lee, Songchun Jiang, Kunyong Yang
  • Pyrimidine derivatives as kinase inhibitors
    Patent number: 8445505
    Abstract: The invention provides novel pyrimidine derivatives of formula (I) and pharmaceutical compositions thereof, and methods for using such compounds. For example, the pyrimidine derivatives of the invention may be used to treat, ameliorate or prevent a condition which responds to inhibition of insulin-like growth factor (IGF-IR) or analplastic lymphoma kinase (ALK).
    Type: Grant
    Filed: June 24, 2009
    Date of Patent: May 21, 2013
    Assignee: IRM LLC
    Inventors: Thomas H. Marsilje, III, Wenshuo Lu, Bei Chen, Xiaohui He, Songchun Jiang, Kunyong Yang
  • Benzene-fused 6-membered oxygen-containing heterocyclic derivatives of bicyclic heteroaryls
    Publication number: 20120289501
    Abstract: The invention relates to new derivatives of formula I, wherein the substituents are as defined in the specification; to processes for the preparation of such derivatives; pharmaceutical compositions comprising such derivatives; such derivatives as a medicament; such derivatives for the treatment of a proliferative disease.
    Type: Application
    Filed: November 23, 2010
    Publication date: November 15, 2012
    Applicant: NOVARTIS AG
    Inventors: Bei Chen, Robin Alec Fairhurst, Andreas Floersheimer, Pascal Furet, Songchun Jiang, Wenshuo Lu, Thomas H. Marsilje, III, Andrea Vaupel
  • ETHER DERIVATIVES OF BICYCLIC HETEROARYLS
    Publication number: 20120165310
    Abstract: The invention relates to compounds of formula I, wherein the substituents are as defined in the specification; to processes for the preparation of such compounds; pharmaceutical compositions comprising such compounds; such compounds as a medicament; such compounds for the treatment of a proliferative disease.
    Type: Application
    Filed: September 10, 2010
    Publication date: June 28, 2012
    Applicant: NOVARTIS AG
    Inventors: Bei Chen, Robin Alec Fairhurst, Andreas Floersheimer, Pascal Furet, Vito Guagnano, Jiang Songchun, Wenshuo Lu, Thomas H. Marsilje, III, Clive McCarthy, Pierre-Yves Michellys, Frederic Stauffer, Stefan Stutz, Andrea Vaupel